John M. Burke, MD, is the Associate Chair of the Hematology Research Program at US Oncology, and a medical oncologist/hematologist at the Rocky Mountain Cancer Centers in Boulder, Colorado. He specializes in blood cancers, with an emphasis on lymphoiddisorders, including lymphomas, chronic lymphocytic leukemia (CLL), and multiple myeloma.
Dr. Burke is considered a national and international expert in blood cancers, lecturing primarily on lymphoid malignancies. He is very active in clinical research, helping to develop new therapies for lymphoid malignancies, and has published numerousarticles in peer-reviewed medical journals, including the New England Journal of Medicine, Blood, and the Journal of Clinical Oncology. He currently serves as Editor-in-Chief for Targeted Therapies in Oncology and as an Associate Editor for JCO OncologyPractice. He is active in hematology and oncology professional societies, having recently served a term on the Ethics Committee of the American Society of Clinical Oncology (ASCO) and currently serving a term on the Committee on Practice of the AmericanSociety of Hematology (ASH). He serves as chair of the US Oncology Pathways Task Force.
Dr. Burke earned his undergraduate degree from Harvard University, where he graduated magna cum laude with an A.B. in History and Science. Dr. Burke went on to earn his medical degree from the Baylor College of Medicine in Houston. He completed a residencyin Internal Medicine at the University of California at San Francisco, and a fellowship in Medical Oncology and Hematology at the Memorial Sloan-Kettering Cancer Center in New York City.